Julian Symons
Direttore Tecnico/Scientifico/R&S presso ALIGOS THERAPEUTICS, INC.
Patrimonio netto: 322 344 $ in data 30/04/2024
Posizioni attive di Julian Symons
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2018 | - |
Storia della carriera di Julian Symons
Precedenti posizioni note di Julian Symons
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2013 | 01/04/2018 |
Formazione di Julian Symons
| University of Central Lancashire | Undergraduate Degree |
| York University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Regno Unito | 2 |
| Canada | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Julian Symons
- Esperienza
